Locally Advanced Pancreatic Cancer Market Report 2026

Locally Advanced Pancreatic Cancer Market Overview

• Locally Advanced Pancreatic Cancer market size has reached to $1.05 billion in 2025 • Expected to grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Impact Of Rising Tobacco Consumption On Health Risks • Market Trend: Innovative Approaches In Treating Rare Cancers With Orphan Drugs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Locally Advanced Pancreatic Cancer Market?

Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures. The therapies available in the locally advanced pancreatic cancer include chemotherapy, immunotherapy, radiation therapy, and surgery. Chemotherapy involves the use of drugs to destroy cancer cells or inhibit their growth. These therapies can be administered through various routes, such as oral, injectable, and others, and are utilized in hospitals, specialty clinics, research institutes, and other healthcare settings.

What Is The Locally Advanced Pancreatic Cancer Market Growth Forecast?

The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to expansion of combination therapy protocols, increasing adoption of SBRT, rising investment in pancreatic cancer research, growing focus on personalized oncology care, increasing availability of advanced treatment centers. Major trends in the forecast period include increasing use of combination chemotherapy regimens, growing adoption of neoadjuvant treatment approaches, rising focus on tumor downstaging for surgical eligibility, expansion of radiation therapy in local disease control, growing emphasis on multidisciplinary treatment planning.

What Is The Driver Of The Locally Advanced Pancreatic Cancer Market?

The increase in tobacco consumption is expected to drive the growth of the locally advanced pancreatic cancer markets going forward. Tobacco is a plant whose leaves are used in products such as cigarettes and cigars. It contains nicotine, which is addictive and is linked to serious health issues such as cancer and heart disease. The rising tobacco consumption is driven by factors such as easy access, affordability, tobacco marketing, social acceptance in some areas, and stress-related smoking. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it contributes to the increased incidence of pancreatic malignancies. For instance, in October 2024, according to the European Respiratory Society's (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increase in tobacco consumption is driving the growth of the locally advanced pancreatic cancer industry.

Key Players In The Global Locally Advanced Pancreatic Cancer Market

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Global Locally Advanced Pancreatic Cancer Market Trends and Insights

Major companies operating in the locally advanced pancreatic cancer market are focusing on developing innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are designed to treat rare diseases affecting a small group of people and are incentivized by authorities with benefits such as tax reductions and market exclusivity to promote their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a new GSK-3β inhibitor, has received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for treating pancreatic ductal adenocarcinoma (PDAC) (a potential types of locally advanced pancreatic cancer). This recognition highlights its potential to fill a critical gap in treating this severe cancer, especially after promising Phase 2 trial results showing significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

What Are Latest Mergers And Acquisitions In The Locally Advanced Pancreatic Cancer Market?

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition aims to enhance the oncology portfolio with advanced radiopharmaceuticals such as FPI-2265, strengthen research and development and manufacturing capabilities, and accelerate the shift to targeted cancer therapies while deepening its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company actively developing targeted therapies for various cancers, including pancreatic cancer.

What Defines the Locally Advanced Pancreatic Cancer Market?

The locally advanced pancreatic cancer market consists of revenues earned by entities by providing services such as chemoradiation, palliative care, targeted therapy, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The locally advanced pancreatic cancer market also includes sales of CT scanners, MRI machines, brachytherapy systems, needle biopsy devices, and hemodynamic monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Locally Advanced Pancreatic Cancer Market Report 2026?

The locally advanced pancreatic cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the locally advanced pancreatic cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.